Suppr超能文献

一种用于追踪植入间充质干细胞的核亲和标记方法的评估

Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells.

作者信息

Leiker Merced, Suzuki Gen, Iyer Vijay S, Canty John M, Lee Techung

机构信息

Center for Research in Cardiovascular Medicine, University at Buffalo, Buffalo, NY, USA.

出版信息

Cell Transplant. 2008;17(8):911-22. doi: 10.3727/096368908786576444.

Abstract

Therapeutic implantation of mesenchymal stem cells (MSCs) is entering the realm of clinical trials for several human diseases, and yet much remains uncertain regarding their dynamic distribution and cell fate after in vivo application. Discrepancies in the literature can be attributed in part to the use of different cell labeling/tracking methods and cell administration protocols. To identify a stem cell detection method suitable for myocardial implantation in a large animal model, we experimented on three different MSC labeling methods: adenovirus-mediated expression of enhanced green fluorescence protein (EGFP) and beta-galactosidase (LacZ), and nuclear staining with DAPI. Intramuscular and intracoronary administrations of labeled porcine MSCs identified the nuclear affinity dye to be a reliable stem cell tracking marker. Stem cell identification is facilitated by an optimized live cell labeling condition generating bright blue fluorescence sharply confined to the nucleus. DAPI-labeled MSCs retained full viability, ceased proliferation, and exhibited an increased differentiation potential. The labeled MSCs remained fully active in expressing key growth factor and cytokine genes, and notably exhibited enhanced expression of the chemokine receptor CXCR4 and its ligand SDF1, indicating their competency in response to tissue injury. Histological analysis revealed that approximately half a million MSCs or approximately 2% of the administered MSCs remained localized in the normal pig heart 2 weeks after coronary infusion. That the vast majority of these identified MSCs were interstitial indicated the ability of MSCs to migrate across the coronary endothelium. No evidence was obtained indicating MSC differentiation to cardiomyocyte.

摘要

间充质干细胞(MSCs)的治疗性植入正进入针对多种人类疾病的临床试验阶段,然而,关于其在体内应用后的动态分布和细胞命运仍有许多不确定因素。文献中的差异部分可归因于使用了不同的细胞标记/追踪方法和细胞给药方案。为了确定一种适用于大型动物模型心肌植入的干细胞检测方法,我们对三种不同的间充质干细胞标记方法进行了实验:腺病毒介导的增强型绿色荧光蛋白(EGFP)和β-半乳糖苷酶(LacZ)的表达,以及用4',6-二脒基-2-苯基吲哚(DAPI)进行核染色。对标记的猪间充质干细胞进行肌肉内和冠状动脉内给药后,确定核亲和染料是一种可靠的干细胞追踪标记物。通过优化活细胞标记条件,产生强烈局限于细胞核的亮蓝色荧光,便于干细胞识别。用DAPI标记的间充质干细胞保持了完全的活力,停止了增殖,并表现出增加的分化潜能。标记的间充质干细胞在表达关键生长因子和细胞因子基因方面仍保持完全活性,并且显著表现出趋化因子受体CXCR4及其配体SDF1的表达增强,表明它们对组织损伤有反应能力。组织学分析显示,冠状动脉输注后2周,约50万个间充质干细胞或约2%的给药间充质干细胞仍定位在正常猪心脏中。这些已识别的间充质干细胞绝大多数位于间质,这表明间充质干细胞有能力穿越冠状动脉内皮。没有获得间充质干细胞分化为心肌细胞的证据。

相似文献

1
Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells.
Cell Transplant. 2008;17(8):911-22. doi: 10.3727/096368908786576444.
2
Tracking of human embryonic stem cell-derived mesenchymal stem cells in premature ovarian failure model mice.
Biochem Biophys Res Commun. 2021 Nov 5;577:6-11. doi: 10.1016/j.bbrc.2021.08.063. Epub 2021 Aug 26.
4
Characterization of EGFP-labeled mesenchymal stem cells and redistribution of allogeneic cells after subcutaneous implantation.
Arch Orthop Trauma Surg. 2008 Jul;128(7):751-9. doi: 10.1007/s00402-008-0585-y. Epub 2008 Feb 12.
7
Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges.
Histol Histopathol. 2013 Sep;28(9):1109-16. doi: 10.14670/HH-28.1109. Epub 2013 Apr 16.
8
Synthetic vascular prosthesis impregnated with mesenchymal stem cells overexpressing endothelial nitric oxide synthase.
Circulation. 2006 Jul 4;114(1 Suppl):I327-30. doi: 10.1161/CIRCULATIONAHA.105.001586.

引用本文的文献

1
Targeted delivery of engineered adipose-derived stem cell secretome to promote cardiac repair after myocardial infarction.
J Control Release. 2025 Jul 10;383:113765. doi: 10.1016/j.jconrel.2025.113765. Epub 2025 Apr 22.
2
Rebuilding the myocardial microenvironment to enhance mesenchymal stem cells-mediated regeneration in ischemic heart disease.
Front Bioeng Biotechnol. 2024 Sep 20;12:1468833. doi: 10.3389/fbioe.2024.1468833. eCollection 2024.
3
Mesenchymal stem cells for critical limb ischemia: their function, mechanism, and therapeutic potential.
Stem Cell Res Ther. 2022 Jul 26;13(1):345. doi: 10.1186/s13287-022-03043-3.
6
Extracellular Vesicles as Therapeutic Agents for Cardiac Fibrosis.
Front Physiol. 2020 May 21;11:479. doi: 10.3389/fphys.2020.00479. eCollection 2020.
8
Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis.
Stem Cells Int. 2020 Mar 9;2020:4356359. doi: 10.1155/2020/4356359. eCollection 2020.
9
Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy.
J Clin Med. 2020 Jan 16;9(1):241. doi: 10.3390/jcm9010241.
10
Improving the engraftment and integration of cell transplantation for cardiac regeneration.
Cardiovasc Res. 2020 Mar 1;116(3):473-475. doi: 10.1093/cvr/cvz237.

本文引用的文献

1
Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation.
Cell Transplant. 2007;16(5):555-62. doi: 10.3727/000000007783464939.
2
Stem cell-based cell therapy for spinal cord injury.
Cell Transplant. 2007;16(4):355-64. doi: 10.3727/000000007783464885.
3
Advances in cell-based therapy for structural heart disease.
Prog Cardiovasc Dis. 2007 May-Jun;49(6):387-95. doi: 10.1016/j.pcad.2007.03.004.
5
Mesenchymal stem cells: a new strategy for immunosuppression?
Trends Immunol. 2007 May;28(5):219-26. doi: 10.1016/j.it.2007.03.001. Epub 2007 Apr 2.
6
Stem cell regulatory function mediated by expression of a novel mouse Oct4 pseudogene.
Biochem Biophys Res Commun. 2007 Mar 30;355(1):111-6. doi: 10.1016/j.bbrc.2007.01.106. Epub 2007 Jan 29.
9
Cellular toxicity induced by SRF-mediated transcriptional squelching.
Toxicol Sci. 2007 Mar;96(1):83-91. doi: 10.1093/toxsci/kfl172. Epub 2006 Nov 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验